Zepbound (Tirzepatide): This weekly injection targets both GLP-1 and GIP receptors, providing significant weight loss benefits
While the study did not evaluate GLP-1 ID specifically, it validated the power of Ivms individualized care model
Four years later, the RECORD was published, which trial enrolled 4,447 patients with uncontrolled T2DM on maximum tolerated monotherapy for at least 2 months and assigned them to rosiglitazone versus sulfonylurea or metformin
Wegovy, for example, can help users lose 15% of their body weight
Insurance is a coin flip: some private plans cover obesity, public plans mostly dont
Additionally, many multi-drug topicals are not available in standard pharmaceutical supply chains